Corroborating evidence indicate that the downregulation of GABA A receptor subunit expression may underlie tolerance to the anticonvulsant and anxiolytic actions of benzodiazepine (BZ) ligands that act as full allosteric modulators (FAMs) of GABA actions at a variety of GABA A receptor subtypes. We and others have shown that 10-14 days treatment with increasing doses of diazepam (a FAM) resulted in anticonvulsant tolerance and decreased the expression of the a1 GABA A receptor subunit mRNA and protein in frontal cortex. In addition, we have also shown that longterm treatment with imidazenil, a partial allosteric modulator of GABA action at selective GABA A receptor subtypes, fail to change the expression of the a1 subunit mRNA or induce tolerance to its anticonvulsant or anxiolytic action. However, little is known regarding the potential role of epigenetic mechanisms on long-term BZinduced downregulation of GABA A receptor subunit. Therefore, we examined the role of histone acetylation and DNA methylation mechanisms on long-term diazepam-induced downregulation of the a1 subunit mRNA expression in rat frontal cortex. We found that 10 days treatment with increasing doses of diazepam but not imidazenil decreased the expression of the a1 GABA A receptor subunit mRNA and promoter acetylation in frontal cortex. In addition, we also found that 10 days treatment with diazepam but not imidazenil increased the expression of histone deacetylase (HDAC) 1 and 2 in frontal cortex. Thus, the increased expression of HDAC1 and HDAC2 (class 1 HDACs) and consequently increased histone deacetylation mechanism of this class 1 HDACs, may underlie long-term diazepam-induced decreased expression of the a1 GABA A receptor subunit mRNA in frontal cortex.
alprazolam) but not those with partial allosteric modulatory (PAM) actions (imidazenil and bretazenil) at a variety of GABA A receptor subtypes has been well established to lead to tolerance and dependence liabilities. [1] [2] [3] Although considerable biochemical and electrophysiological evidence suggests that tolerance to the anxiolytic and anticonvulsant effects of FAM are associated with downregulation of receptor subunits expression and GABA A receptor function, 4-9 the precise molecular mechanism underlying the downregulation of GABA A receptor subunits function is still not understood.
It is now widely recognized that epigenetic mechanisms such as DNA promoter methylation, histone acetylation, and methylation play significant roles in the pathophysiology of brain disorders including addictive behaviors, tolerance, and dependence liabilities. [10] [11] [12] [13] [14] Histone tail lysine acetylation which involves the addition of acetyl groups to lysine residues on histone tails leads to a relaxed (open) chromatin structure and consequently the activation of target gene expression. In addition, the acetylation of histone tails is also regulated by histone acetyltransferases and histone deacetylases. [15] [16] [17] Conversely, DNA promoter methylation which involves the covalent coupling of a methyl group to the C5 position of cytosine residues of CpG dinucleotide upstream of the transcription start site, is catalyzed by DNA methyltransferases [DNA methyltransferase 1 (Dnmt1), DNA methyltransferase 3a (Dnmt13a) DNA methyltransferase 3b (Dnmt3b) DNA methyltransferase 3 l (Dnmt3 l)] and is generally associated with gene silencing. 11, 12 Recent studies have also shown that DNA methylation is kept in a steady state by the action of a demethylase system which includes a first step 5-hydroxy methylation driven by ten-eleven translocase (TET) enzymes. 18 The role of these enzymes is difficult to establish because of the lack of specific pharmacological agents targeting these enzymes.
Histone acetylation and DNA methylation are targeted by histone deacetylase (HDAC) inhibitors and DNA methyltransferase inhibitors, respectively. 10, 11, 18 Thus, the epigenetic regulation of targeted gene expression with selective pharmacotherapeutic strategies is increasingly becoming a viable alternative for the design and development of new therapeutic strategies to treat specific types of malignancies and neuropsychiatric disorders such as Huntington disease, schizophrenia and depression. [19] [20] [21] [22] [23] [24] Interestingly, it has also been reported that chronic antidepressant-induced increase acetylation status of histone proteins in frontal cortex and hippocampus contributes to the therapeutic effects of antidepressant interventions. 25 These findings raise the possibility that long-term diazepam exposure may lead to alterations of epigenetic mechanisms regulating the expression of a1-GABA A receptor subunit resulting to the downregulation of this receptor subunit, and a process that may underlie tolerance to the pharmacological actions of diazepam.
We and others have previously shown that long-term treatment of rats with increasing doses of diazepam or triazolam (FAMs) for 10-14 days induced anticonvulsant tolerance and decreased expression of mRNA and protein encoding for the a1 GABA A receptor subunit in prefrontal cortex. 2, 7, 8, 26, 27 In contrast, long-term treatment with equipotent anti-bicuculline doses of partial allosteric modulators (PAM) of GABA A receptors (imidazenil or bretazenil) fail to elicit anticonvulsant tolerance or change the expression of mRNA and protein encoding for a1 GABA A receptor subunit. 7, 8, 26, 27 until used for RT-qPCR, ChIP assay or western blot.
| RNA extraction and real-time polymerase chain reaction (PCR) quantification
Total RNA was isolated from frontal cortices using TRIzol reagent and further purified using Qiagen RNeasy Kit. Total RNA was con- 
| Chromatin immunoprecipitation assay
In order to establish a possible role for epigenetic mechanisms in long-term diazepam-induced downregulation of a1 GABA A receptor subunit mRNA expression, we examined DNA methylation, histone acetylation, and methylation levels at a1 GABA A receptor subunit promoter in frontal cortex. We used specific antibodies against H3K9me2, MeCP2, and acetylated histone H3 for chromatin immunoprecipitation (ChIP) assay as previously described. 34, 35 In brief, frontal cortices were fixed in methanol-free 1% formaldehyde by incubating on a rocking platform at room temperature for 15- receptor subunit promoter while imidazenil treatment had no effect.
| Western blot
These results indicate that only long-term diazepam treatment resulted in a significant reduction of the level of acetylated histone H3 at a1GABA A receptor subunit promoter thereby leading to a decreased expression of this receptor subunit in frontal cortex. Thus long-term diazepam exposure will most likely result to the induction of chromatin and synaptic remodeling in frontal cortex.
| Long-term diazepam treatment alters the expression of HDAC1 and HDAC2 but not HDAC3
Since long-term diazepam treatment decreased the levels of acetylated histone H3 at a1-GABA A receptor subunit promoter, we also 50, 51 and may also repress the transcription of the a1 receptor subunit by recruiting HDAC1 and HDAC2 to this GABA A receptor subunit promoter complex. Thus, HDAC1 and HDAC2-mediated histone deactylation at the a1 GABA A receptor subunit promoter may trigger the signaling mechanisms that underlie the downregulation of the a1 subunit that is associated with long-term benzodiazepine treatment.
Accordingly, pretreatment or concurrent treatment with selective HDAC1 and HDAC2 inhibitors might prevent the decrease in a1
GABA A receptor subunit expression associated with chronic benzodiazepine treatment. Therefore future experiments will examine whether concurrent treatment with selective HDAC inhibitors will attenuated the decrease a1 subunit expression associated with anxiolytic and anticonvulsant benzodiazepines tolerance and/or dependence.
In conclusion, the outcome of our study points to a new and important role for histone deacetylation in chronic benzodiazepineinduced downregulation of a1 GABA A receptor subunit expression.
However, further studies will be needed to establish whether the 
